Clinic Perks
Spoken Languages


Our Price

Package Details

We provide professional support in RETINA.




he retina is a layer of the eyeball lining its back wall, which consists of light-sensitive cells. Retinal diseases threaten our sight directly.

Retinal Diseases

• Hemorrhages related to diabetes and hypertension

• Retinal vein occlusions

• Retinal detachment / tears

• Yellow spot disease

• Congenital retinal diseases

• Fluid retention under the retina, retinal edema

• Foreign bodies in the eye

• Macular holes

• Vitreoretinal surface disorders

• Retinal tumors

Symptoms of Retinal Disease 

• Sudden or gradual loss of vision

• Distorted vision

• Flashes

• Eye floaters

• Curtained vision

• Temporary, short-term loss of vision

• Dark areas in the field of vision

Negative Effects of Diabetes and Hypertension on the Retina 

Diabetes and hypertension have adverse effects on all the body’s systems and their first and most important adverse effect occurs in the eyes. Dilatation of the retinal vessels and permeability impairments occur as a result of these diseases.

Treatment of Retinal Diseases at Dünyagöz 

Early diagnosis, preventive medical therapy and undelayed accurate surgical intervention is of vital importance in retinal diseases. At Dünyagöz, retinal surgeries are performed by a team which has been specially trained for intraocular microsurgeries, using a comprehensive set of instruments and devices.


Retinal detachment develops due to tears or holes in the retina. It is frequently seen in patients with high myopia. It may develop at any age but more in middle-aged and elderly people.

The retinal layer becomes strained as the eye’s anteroposterior diameter increases and the strained area starts to thin and break down. Sporadic thinning and breaking down can occur around the retina in some familial or degenerative diseases and infections too. Meanwhile, the vitreous gel starts to lose its homogeneity and deteriorate for the same reasons; the gel’s consistency changes and it slowly separates from the retina. This separation is called vitreous detachment. The vitreous tissue shrinks and becomes opaque at places; as it passes the eye’s visual axis, the person perceives this as eye floaters or a curtain of smoke. Retinal detachment may lead to partial or total loss of vision if not treated without delay by a doctor who is experienced in retinal diseases.

Causes and Symptoms of Retinal Detachment

If untreated, retinal diseases may result in permanent blindness.  Symptoms such as glare, floaters or sudden loss of vision may indicate a significant eye disease like retinal detachment. Results which may lead to loss of vision can be prevented through early diagnosis, detailed examination and a timely – and most important of all, accurate – treatment. Retinal surgeries are major operations which require important sterilization measures and use of high technology and otherwise may result in loss of vision.

When the macula (the eye’s visual center) separates from the tissue underneath, central vision is lost. In long-term detachment, intraocular balances are disrupted and the eyeball starts to get smaller. Sudden, severe or perforating trauma to the eye can be a cause of detachment. In diabetes and some degenerative diseases, strands are formed in the vitreous that pull away at the retina, leading to traction-related detachment. Though rare, detachments may develop without any tearing in the eye, as in certain infections, tumors and especially hypertensive crises that occur during pregnancy.



The most common cause of diabetes-related blindness is “Diabetic Retinopathy”.

Diabetes is a metabolic disease characterized by elevated blood glucose as a result of insufficient release or action of insulin.

Diabetes particularly affects the eye’s neural layer (retina) and the capillary vessels in this layer, disrupting their function and leading to loss of vision. Retinal disorders associated with diabetes are called diabetic retinopathy.

In diabetic patients, an eye examination should be performed from adolescence on in young people and at the time of diagnosis in individuals that develop diabetes after 30 years of age. If their retina is normal, an annual eye examination should be performed in diabetic patients. Once a retinopathy starts, the interval of check-ups can be reduced to 3-4 months.

Causes of Diabetic Retinopathy 

The primary risk factor for diabetic retinopathy is the duration of diabetes. The incidence of retinopathy increases particularly after the 10th year following the diagnosis of diabetes. In young patients with type 1 or insulin-dependent diabetes, the incidence of retinopathy increases with age after adolescence.

Keeping blood glucose under control is an important factor. Unstable blood glucose levels and sudden increases and decreases in blood glucose make retinal deterioration and disease progress easier. Pregnancy, hypertension, elevated blood fats (hyperlipidemia) and kidney disease are factors aggravating retinopathy.

Diabetes damages retinal capillary vessels, causes cell loss, disrupts vessel permeability and causes retention of fluid and fatty substances in the macular area, hence obstruction of capillaries, leading to areas with no blood supply. New vessels are formed in the retina which can bleed spontaneously. Bleeding occurring in front of and inside the retina may leak into the eye’s posterior chamber. Venous membranes are formed in the retina, leading to serious losses of vision and painful elevations in eye tension.



Yellow spot disease (macular degeneration) is a retinal disease that affects

central vision. It is quite common after the age of 55 and may lead to loss of vision in the event of progression.

Who does yellow spot disease affect? 

• People older than 55 years of age

• Those with hereditary risk

• Smokers

Risk Factors

The main risk factors for age-related yellow spot disease include the person’s age and hereditary characteristics. Other risk factors are hypertension, smoking, nutrition, elevated lipid-cholesterol levels, long-term exposure to sunlight and being overweight.

Symptoms of the Disease

• Loss of vision

• Wavy or broken view of objects/lines

• Shadows in front of the eye

• Impaired visual quality

• Trouble discerning colors

Age-related and hereditary factors are impossible to eliminate. However, other risk factors can be controlled. If there is hypertension, it can be controlled. If smoking, the patient should quit. Filter sunglasses should be worn for sun protection. A Mediterranean diet is recommended. It is recommended to avoid butter, red meat and cholesterol-containing food.

How many types of yellow spot disease are there and what are their results?

There are two types of yellow spot disease; dry and wet. The dry type accounts for 90% and the wet type accounts for 10% of all cases. However, early diagnosis is more important in the wet type since it leads to loss of vision. Progressing more rapidly than the dry type, this disease leads to sudden loss of vision accompanied by impaired color vision and a loss in contrast sensitivity, and to blindness because of bleeding in the new vessels that are formed in the retina and macula over time.

Treatment of Yellow Spot Disease

Preventive treatment is given in the dry type of yellow spot disease;  intraocular injection and photodynamic treatment is administered in the wet type. Antioxidant vitamins A, C and E, lutein and zinc are used in preventive therapy. Intraocular injections are made by numbing the eye with an eye drop. The patient feels no pain during this procedure. In photodynamic therapy, a drug called verteporfin is first administered intravenously in a special combination and a low power laser is then applied.

Drug Injection in the Treatment of Yellow Spot Disease

A kind of protein (anti-VEGF antibody) is used for intraocular injection therapy. FDA-approved anti-VEGF drugs are injected into the eye with a needle for treatment of the wet type of yellow spot disease, which occurs in one in every three people aged 75-85 years. The anti-VEGF drug used during the treatment inhibits the protein which is released by the eye cells behind the eye in the event of disease and forms new vessels, thus preventing loss of vision. Injected into the eye at 4-6 week intervals, the drug stops the development of new vessels in the yellow spot and improves the patient’s complaints significantly. The injection is made at least 3 times but some patients require more. Injection intervals vary between 4-6 weeks depending on the patient’s response to therapy.

If untreated, yellow spot disease results in 95% loss of vision and ultimately in total loss of vision. Vision is reduced to a level which is legally accepted as blindness and patients become unable to see what they are looking at. For instance, the patient cannot see the face of the person in front of them, but can see their

arm or leg. These patients usually cannot leave their house alone; they can do their house chores by themselves but need the help of others in many tasks. Since they can’t see, they can’t read, write, watch TV or drive.

Amsler Grid Test in Yellow Spot Disease

This test is not the equivalent of a routine eye exam. However, it is a graph that you can self-administer to identify the early symptoms of yellow spot disease. Experts recommend that everyone older than 40 years of age take this test.


Method of Administering the Amsler Grid Test

• Wear your eyeglasses or contact lenses if you use a pair.

• In a well-lit room, hold the above graph approximately 30-40 cm away from your face in a fixed way.

• Cover one eye with your hand and focus on the dot in the middle. You should be able to see all 4 corners of the large square in the


• Test your other eye in the same way.

• You could have symptoms of yellow spot disease if the lines appear wavy, broken or blurry or if you can’t see the corners.

In that case, you should see an ophthalmologist specialized in retinal diseases as soon as possible.



What is retinopathy of prematurity? 

Retinopathy of prematurity is described as one of the most important eye health issues affecting premature babies. Vessels in the eyes of infants continue to develop until the time of birth. In premature babies, such development continues after birth since it is not completed yet. High concentrations of oxygen given to keep premature babies alive cause the vessels in the eyes to develop abnormally. As a result, retinopathy of prematurity (shortly called ROP) develops in the retinas of infants whose vascularization is not complete. Unless treated at an early period, this leads to blindness in both eyes. Therefore, premature babies should be examined by an ophthalmologist.

Which babies does retinopathy of prematurity affect most? 

A normal pregnancy lasts 40 weeks or 280 days. If delivery takes place before week 37 is completed, the baby is considered to be premature. Infants born weighing less than 2,500 grams are termed “low birthweight” babies. Two thirds of these infants are premature babies.

Retinopathy of prematurity is most common in those whose birthweight is less than 1000 grams. Therefore, all infants born weighing less than 1500 grams and earlier than week 32 should be examined for ROP. Early diagnosis and treatment of ROP in newborns is possible through the collaboration of specialist pediatricians and ophthalmologists. Pulmonary and coronary disorders, severe infections and any brain-related problems occurring in infants also increase the risk of retinopathy. Treatment with early diagnosis is possible; delayed treatment results in blindness in both eyes.

When should babies have their eye examination?

An eye examination should be performed 4-6 weeks after birth. ROP has five stages from mild to severe and success is correlated with disease stage. Follow-up is sufficient in the first two stages; from the third stage on laser and cryo treatment should be started because the best results are achieved in the third stage. In the fourth and fifth stages, the result of the necessary surgical intervention is not successful. Performing an eye examination in the first month following birth is important for all newborns since timely diagnosis and successful treatment is made possible not only for ROP but also for many eye diseases including high eye pressure, lazy eye, lacrimal duct occlusion and strabismus.

Pediatric Anesthesia

FDA (American Food and Drug Administration)-approved technologies and materials are used in the monitoring and treatment of pediatric eye diseases. If anesthesia is required, it is administered by anesthesiologists specialized in pediatric anesthesia. Anesthesia is given in sterile operating rooms, on operating tables designed to fit pediatric patients and using personal, single-use medical supplies.

Additional information


No more offers for this product!
Joined: 37 months
Visit Hospital / Clinic


Initiating its services in 1996, Dünyagöz Hospitals Group brings solutions to all kinds of problems related to ocular and periocular health with hundreds of different treatment methods provided in all eye-related branches using state-of-the-art technologies. Beginning a new era with branch hospital services in Turkey, Dünyagöz Hospitals Group provides its health services both domestically and internationally at a total of 29 different locations with a daily capacity of 8000 outpatients and 1000 surgical operations.

Dünyagöz Hospitals Group has taken its place among the few exceptional centers worldwide within a short time, with its continuously renewed and comprehensive technology, its experienced medical staff of 300 members consisting of lecturers and specialists, its staff of approximately 2,500 employees and its contemporary understanding of management. Dünyagöz Hospitals Group offers eye-care services with 20 branches in 11 provinces throughout Turkey, including İstanbul, Ankara, Antalya, İzmit, Adana, Samsun, Tekirdağ, Bursa, Konya, Sakarya and Gaziantep, and also provides services in 9 different international locations in Frankfurt and Köln, Germany, in Tbilisi, Georgia, in Baku, Azerbaijan, Amsterdam and Nijmegen, in the Netherlands. Intending to expand its operations to an even wider region with a new center in İzmir in 2021 while maintaining the pace of its investments and leading the health tourism activities in Turkey, the Group offers services for approximately 96,000 patients a year from 147 foreign countries around the world.

ACIBADEM 14 products

Oral and Dental Health
Oral, Dental and Maxillofacial Surgery
Aesthetic, Plastic and Reconstructive Surgery

Adem & Havva Clinic 12 products

Hair Transplant for Men
Hair Transplant for Women
Eyebrow Transplant
Beard and Mustache Transplant

Bahçeci Fertility 1 products

Infertility and IVF

Chemothermia 0 products

Dentadent 9 products

General Anesthesia / Sedation
Endodontics – Root Canal Treatment
Restorative Tooth Treatment
Oral Diagnosis - Radiology

dentisland 12 products

Oral , Dental and Maxillofacial Surgery
Endodontics – Root Canal Treatment
Cosmatic Dentistry

DünyaGöz 14 products

Eye Laser Surgery

FBMClinic 0 products

Florence Nightingale 12 products

Plastic and Reconstructive Surgery Center
Eye Diseases & Laser Center
Nuclear Oncology (Nuclear Medicine)

istanbulhospital 5 products


MedicalPark 10 products

Oral and Dental Health
Eye Health & Diseases
Medical Oncology

Medicana 49 products

Dental Cosmetics – Whitening
Fertiliy Center - IVF
Face Lift

Medipol 17 products

Posthetic (Prostheses) dentistry
Medical Oncology
Oncology ( Cancer Treatment )

Mefdental 9 products


memorial 10 products

Oral and Dental Diseases
Aesthetic, Plastic and Reconstructive Surgery
Eye Center
Gynecological Oncology (Gynecologic Cancers)

Romatem 14 products

Stroke Rehabilitation
Spinal cord injuries
Multiple Sclerosis
Cerebral Palsy (CP)

ROMMER 36 products

Brachial Plexus Rehabilitation
Parkinson’s Disease Rehabilitaion.
Walking and Balance Disorder Rehabilitation
Orthopedic Rehabilitation

TOTM MALATYA 0 products

TürkiyeHastanesi 5 products

Dental Specialities
Ophtalmology and Laser Center
Orthopedics, Spine Center and Traumatology